EU Patent Office Approves ARS Pharma’s Neffy Nasal Spray
ARS Pharmaceuticals secured a significant intellectual property win in Europe, with the European Patent Office’s Opposition Division upholding all...
AI Drug Discovery AstraZeneca BIO-Europe Spring 2026 biopharma M&A biopharma strategy biotech funding biotech strategy business development cancer immunotherapy China Biotech CNS Pipeline Strategy competitive intelligence Disease-Modifying Therapy Drug Pricing Strategy eClinical Tech News Eli Lilly Emerging Markets FDA Approval FDA Priority Review HER2 Oncology immuno-oncology immunology licensing deals Lifecycle Management Market Access Medtronic MSS colorectal cancer Novo Nordisk Obesity/GLP-1 Obesity Drug Market Obesity Market Oncology Pipeline Patent Cliff Priority Review Voucher pulmonary hypertension Rare Disease Regeneron respiratory biologics Roche Sanofi series A funding Teva Pharmaceuticals Type 1 Diabetes Type 2 Diabetes venture capital
No videos found.
ARS Pharmaceuticals secured a significant intellectual property win in Europe, with the European Patent Office’s Opposition Division upholding all...
Lexicon Pharmaceuticals convened a policy roundtable in Washington, DC, centered on expanding federal support for non-opioid pain treatments. The...
Abeona Therapeutics has activated Children’s Hospital Colorado as a qualified treatment center for Zevaskyn (prademagene zamikeracel), the first FDA-approved...
Nilo Therapeutics has launched with a $101 million Series A to develop drugs that modulate neural circuits to restore...
Newcastle University has partnered with Curium to establish a PET radiopharmaceutical manufacturing site in Newcastle, expected to be operational...
Zenas Biopharma has secured a global license from InnoCare Pharma to develop and commercialize orelabrutinib for multiple sclerosis and...
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions have launched an integrated CMC partnership to deliver end-to-end...
Reviva Pharmaceuticals is convening a key opinion leader webinar on October 10 to discuss Phase 3 data for brilaroxazine,...
Neurogastrx will present proof-of-concept data for NG101, an oral, peripherally restricted dopamine D2 receptor antagonist (metopimazine mesylate), in semaglutide-induced...
Akero Therapeutics will deliver two oral presentations and a poster at AASLD’s The Liver Meeting 2025, highlighting 96-week Phase...
